Related Experiment Video

Updated: Jun 26, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

419

GSG2 promotes progression of human endometrial cancer by regulating PD-1/PD-L1 expression via PI3K-AKT pathway

Hong Chen1, Shuxi Liu1, Sikao Wu1

  • 1Department of Gynecology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, PR China.

International Immunopharmacology
|May 17, 2024
PubMed

Insights

Overexpression of GSG2 kinase promotes endometrial cancer (EC) by disrupting cell cycle and immune response. Targeting GSG2 may offer a new therapeutic strategy for EC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cell cycle dysregulation is a hallmark of cancer, driving uncontrolled proliferation.
  • GSG2 (Haspin) is a kinase involved in mitosis, and its overexpression is linked to various cancers.

Purpose of the Study:

  • Investigate the role of GSG2 as a tumor promoter in endometrial carcinoma (EC).
  • Examine the relationship between GSG2 expression and the tumor's immunological microenvironment.

Main Methods:

  • Immunohistochemistry to correlate GSG2 with EC development and prognosis.
  • In vitro cell and in vivo animal experiments to assess GSG2's protumorigenic function.
  • GeneChip analysis and tumor-immune coculture models to study immune microenvironment interactions.

Main Results:

  • GSG2 overexpression was correlated with EC development and prognosis.
  • GSG2 demonstrated a protumorigenic phenotype in EC cell lines and animal models.
  • GSG2 expression was linked to alterations in the immune microenvironment composition.

Conclusions:

  • GSG2 acts as a tumor promoter in EC by potentially activating the PI3K/AKT pathway.
  • GSG2 influences DNA repair, cell cycle regulation, and immune response in EC.
  • GSG2 represents a potential therapeutic target for endometrial carcinoma.
Keywords:
Endometrial cancerGSG2Immune microenvironmentPD-1/PD-L1PI3K/AKT signaling

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.5K
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

12.9K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K